Article
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.
Cell - 6 Feb 2020
Schommers Philipp, Gruell Henning, Abernathy Morgan E, Tran My-Kim, Dingens Adam S, Gristick Harry B, Barnes Christopher O, Schoofs Till, Schlotz Maike, Vanshylla Kanika, Kreer Christoph, Weiland Daniela, Holtick Udo, Scheid Christof, Valter Markus M, van Gils Marit J, Sanders Rogier W, Vehreschild Jörg J, Cornely Oliver A, Lehmann Clara, Fätkenheuer Gerd, Seaman Michael S, Bloom Jesse D, Bjorkman Pamela J, Klein Florian
Abstract excerpt
Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope glycoprotein (Env) limits clinical applications. Here we describe 1-18, a new VH1-46-encoded CD4 binding site (CD4bs) bNAb with outstanding breadth (97%) and potency (GeoMean IC50 = 0.048 μg/mL). Notably, 1-18 is not susceptible to typical CD4bs...
Topics
- Animals
- Antibodies, Monoclonal
- Binding Sites
- Broadly Neutralizing Antibodies
- CD4 Antigens
- CHO Cells
- Cohort Studies
- Cricetulus
- Epitopes